GLP1R and colorectal cancer: Moreover, Wang et al. found in another TriNetX study a 23% lower rate (HR = 0.77; 95% CI, 0.59–1.00) in colorectal cancer with GLP‐1 RAs versus DPP‐4i in drug‐naïve people with T2D and overweight or obesity, an effect size similar to our findings for semaglutide.